Biogen Q2 2026 revenue rises 3% to $2.7 billion
Biogen reported $2.7 billion in second quarter revenue, up 3% year-over-year, with strong contributions from growth portfolio products and the recently acquired Apellis assets.
View filing at SEC.gov →5 most recent filings and news items mentioning BIIB. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/BIIB/news?limit=20"
Pull BIIB filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayBiogen reported $2.7 billion in second quarter revenue, up 3% year-over-year, with strong contributions from growth portfolio products and the recently acquired Apellis assets.
View filing at SEC.gov →This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
View filing at SEC.gov →Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping List
View filing at SEC.gov →This House of Representative Just Bought Up To $375K In Biogen Stock
View filing at SEC.gov →The Phase 2b LUMA study of BIIB122 failed to meet primary and secondary endpoints in early-stage Parkinson's disease, prompting discontinuation in idiopathic PD while continuing a separate LRRK2 carrier study. The setback represents a significant clinical disappointment for both
View filing at SEC.gov →